Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells 658 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 658 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total value of $65,800.00. Following the transaction, the senior vice president directly owned 616 shares in the company, valued at approximately $61,600. This represents a 51.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe also recently made the following trade(s):

• On Tuesday, August 18th, Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $100.00, for a total value of $4,000,000.00.
• On Monday, August 3rd, Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $105.29, for a total value of $193,733.60.
• On Wednesday, July 1st, Jolanda Howe sold 2,721 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $120.00, for a total transaction of $326,520.00.
• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $101.95, for a total transaction of $264,458.30.

Mirum Pharmaceuticals Trading Up 0.8%

Shares of Mirum Pharmaceuticals stock traded up $0.80 during trading on Thursday, reaching $100.63. 453,033 shares of the stock were exchanged, compared to its average volume of 857,573. Mirum Pharmaceuticals, Inc. has a 1 year low of $63.23 and a 1 year high of $130.00. The firm has a market cap of $6.53 billion, a price-to-earnings ratio of -6.92 and a beta of 0.49. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The stock’s fifty day moving average is $109.55 and its 200 day moving average is $101.74.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The business had revenue of $176.24 million during the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The company’s quarterly revenue was up 37.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.12) EPS. As a group, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

MIRM has been the topic of a number of research analyst reports. CLSA set a $146.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $137.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. Weiss Ratings raised shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. HC Wainwright lowered their price objective on shares of Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Finally, Wall Street Zen raised Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, August 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $137.31.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Nan Fung Trinity HK Ltd. increased its stake in Mirum Pharmaceuticals by 45.6% during the 4th quarter. Nan Fung Trinity HK Ltd. now owns 227,479 shares of the company’s stock valued at $17,969,000 after purchasing an additional 71,214 shares in the last quarter. BlackRock Inc. bought a new position in shares of Mirum Pharmaceuticals in the second quarter worth approximately $513,945,000. SBI Okasan Asset Management Co.Ltd. bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth approximately $1,283,000. Emerald Advisers LLC grew its holdings in shares of Mirum Pharmaceuticals by 8.2% during the first quarter. Emerald Advisers LLC now owns 397,263 shares of the company’s stock valued at $36,699,000 after buying an additional 30,129 shares during the last quarter. Finally, Rice Hall James & Associates LLC purchased a new stake in shares of Mirum Pharmaceuticals during the second quarter valued at approximately $12,956,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.